EdisonNTanMD

Geriatric Medicine, Hospital Medicine/Hospitalist, Healthcare Research and Healthcare Policy, Medical Information Sciences

Florida Medical Center Outpatient Center Morton Plant Meases Hospitalist HCR Medical Director Principal Investigator of Clinical Trials

Dr. Tan is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Dr. Edison Tan is an internist in Clearwater, FL and is affiliated with Morton Plant Hospital. He received his medical degree from Far Eastern University Nicanor Reyes Medical Foundation and has been in practice for over 20 years. He also speaks multiple languages, including Chinese (Mandarin) and Filipino. He is experienced in geriatrics, metabolic syndrome and weight loss. He is also a pricncipal investigator of cardiovascular diseases research and a major COVID studies. Dr. Tan provides consultation for the health industry, political and non-profit organizations.

Cook County Health and Hospitals SystemResidency, Internal Medicine, 1998
Cook County Health and Hospitals SystemInternship, Internal Medicine, 1995 - 1996
Far Eastern University Nicanor Reyes Medical FoundationClass of 1993

CMS Meaningful Use Stage 1 Certification eClinicalWorks EHR, eClinicalWorks LLC, 2013

PubMed

Journal Articles

Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19
Myron J. Levin, M.D, nejm, 4/20/2022
Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen (PRECISION)
Steven E. Nissen, MD, MACC, NEJM, 4/12/2016
COMPARE: comparison of the effects of carvedilol CR and carvedilol IR on left ventricular ejection fraction in patients with heart failure
Barry H Greenberg 1, Mandeep Mehra, John R Teerlink, Paul Ordronneau, David McCollum, Edward M Gilbert, American Journal of Cardiology, 10/2/2006

Abstracts/Posters

Evusheld long-acting antibody combination retains neutralising activity against Omicron variant in independent FDA study
Aztra Zeneca, Press Release, Global, 11/16/2021
AZD7442 PROVENT Phase III prophylaxis trial met primary endpoint in preventing COVID-19
Adrian Kemp Astra Zeneca, Press Release, Global, 8/20/2021

Lectures

Principal StudyA Phase III Multi-center, Open-label Sub-study in Adults to Assess the Safety, PK, and Immunogenicity of Repeat Doses of AZD7442, a Combination Product of Two Monoclonal Antibodies (AZD8895 and AZD1061)
Principal InvestigatorProspective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen
Principal InvestigatorA Study to Compare the Effects of Coreg CR and Coreg IR on Heart Function in Subjects With Stable Chronic Heart Failure
Principal InvestigatorEvusheld long-acting antibody combination retains neutralising activity against Omicron variant in independent FDA study